Corrections:

Suthakar Ganapathy^1,*, Bo Peng^1,*, Ling Shen¹, Tianqi Yu¹, Jean Lafontant¹, Ping Li^2,3, Rui Xiong³, Alexandros Makriyannis¹ and Changyan Chen¹

¹Center for Drug Discovery, Northeastern University, Boston, MA, USA
²The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China
³The Institute of Clinic Sciences, Sahlgrenska Academy, Gothenburg, Sweden
^*These authors contributed equally to this work

Published: February 25, 2023

Copyright: © 2023 Ganapathy et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 3, the panel B image of MIA - MnSOD contains an accidental duplicate of the Figure 6, panel B image of MIA - GADD153. The corrected Figure 3B, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:30992–31002. DOI: https://doi.org/10.18632/oncotarget.16047

Figure 3: ROS regulators were activated after co-suppression of PKC α and β. (B) MnSOD expression in the cells after the treatments was analyzed by immunoblotting.